Landmark MVA for PFS and OS by baseline and response characteristics
| Characteristic . | Median PFS (mos) . | HR (95% CI) . | P . | Median OS (mos) . | HR (95% CI) . | P . |
|---|---|---|---|---|---|---|
| Absence of del(17p) | NR | 0.05 (0.01-0.2) | <.001 | NR | 0.3 (0.09-0.9) | .05 |
| CR | NR | 0.2 (0.05-0.9) | .04 | NR | 0.3 (0.1-0.8) | .02 |
| MRD response-negative | NR | 0.1 (0.01-0.9) | .04 | NR | 0.7 (0.5-0.9) | .05 |
| Characteristic . | Median PFS (mos) . | HR (95% CI) . | P . | Median OS (mos) . | HR (95% CI) . | P . |
|---|---|---|---|---|---|---|
| Absence of del(17p) | NR | 0.05 (0.01-0.2) | <.001 | NR | 0.3 (0.09-0.9) | .05 |
| CR | NR | 0.2 (0.05-0.9) | .04 | NR | 0.3 (0.1-0.8) | .02 |
| MRD response-negative | NR | 0.1 (0.01-0.9) | .04 | NR | 0.7 (0.5-0.9) | .05 |
The HRs were adjusted from the multivariable Cox regression model. Variables not significant (P > .05) on MVA for PFS: age ≥65 years; B2M ≥4 mg/L; unmutated IGHV gene; ZAP70 positive; overall remission. Variables not significant (P > .05) on MVA for OS: age ≥65 years; B2M ≥4 mg/L; overall remission.
mos, months; NR, not reached.